| Cat.No. | Product Name | Information | Product Use Citations | Product Validations |
|---|---|---|---|---|
| S2215 | DAPT | DAPT is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. DAPT enhances the apoptosis of human tongue carcinoma cells and regulates autophagy. |
|
|
| S1575 | RO4929097 (RG-4733) | RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2. |
|
|
| S2714 | LY411575 | LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch cleavage with IC50 of 0.39 nM in APP or NΔE expressing HEK293 cells. LY411575 induces apoptosis. |
|
|
| S7169 | Crenigacestat (LY3039478) | Crenigacestat (LY3039478) is an oral Notch and gamma-secretase inhibitor with IC50 of 0.41 nM for Notch. |
|
|
| S7399 | FLI-06 | FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM. |
|
|
| S8280 | IMR-1 | IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 26 μM. |
|
|
| S3376 | RIN1 (RBPJ Inhibitor-1) | RIN1 (RBPJ Inhibitor-1) is a potent inhibitor of the transcription factor RBPJ that disrupts the interaction between NOTCH and RBPJ. |
|
|
| S9719 | Limantrafin (CB-103) |
An orally active inhibitor of the Notch transcription activation complex, Limantrafin (CB-103) produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth of human breast cancer and leukemia xenografts. |
|
|
| E6836New | Yhhu-3792 hydrochloride | Yhhu-3792 hydrochloride is a Notch activator that enhances the self-renewal capability of neural stem cells (NSCs) and promotes the expression of Hes3 and Hes5. It increases the spatial and episodic memory abilities of mice by expanding the NSC pool and promoting endogenous neurogenesis in the hippocampal dentate gyrus. It exhibits potential to be used in the study of neurodegenerative diseases such as Alzheimer's disease, or for neural regeneration after brain injury. | ||
| S6668 | NVS-ZP7-4 | NVS-ZP7-4,a Zinc transporter SLC39A7 (ZIP7) inhibitor,is the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway. | ||